A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination With FOLFOX + Bevacizumab/Cetuximab in Subjects With Advanced Colorectal Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs LEAC 102 (Primary) ; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Taiwan Leader Biotech Corp
- 07 Jun 2017 Biomarkers information updated
- 24 Apr 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jun 2017.
- 28 Dec 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Feb 2019.